Indication
Multidrug-resistant tuberculosis
6 clinical trials
22 products
Clinical trial
STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TBStatus: Completed, Estimated PCD: 2022-05-13
Product
Regimen AProduct
MoxifloxacinProduct
ClofazimineProduct
EthambutolProduct
PyrazinamideProduct
IsoniazidProduct
ProthionamideProduct
KanamycinProduct
LevofloxacinProduct
BedaquilineClinical trial
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium TuberculosisStatus: Recruiting, Estimated PCD: 2025-04-01
Product
TedizolidProduct
LinezolidProduct
Standard quadruple therapyClinical trial
Refining Multidrug Tuberculosis Treatment With the Ultra Short All Oral RegimenStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Product
Standardized Shorter RegimenClinical trial
A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-08-28
Product
TBAJ-876Product
MidazolamClinical trial
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (TB-TRUST)-PLUSStatus: Active (not recruiting), Estimated PCD: 2023-04-30
Product
CycloserineProduct
DigoxinProduct
TLDClinical trial
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical TrialStatus: Completed, Estimated PCD: 2022-05-10
Product
Pretomanid